BioSpace News Archive

Drug Development

Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced positive results from the 350 mg weekly dose of its Phase 2 NASH clinical trial.

January 5, 2022
·
12 min read
Business

Cytek® Biosciences Expands Fremont Headquarters, Tripling Its Manufacturing Capacity Operations to Accommodate Increasing Demand for Cell Analysis Solutions

Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that it has opened a new facility in Fremont, California – tripling its current manufacturing capacity in order to meet growing global demand for cell analysis solutions.

January 5, 2022
·
6 min read
Business

Elevar Therapeutics Announces Appointment of Jenny Gizzi to Chief People Officer

Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, announced the appointment of Jenny Gizzi to Chief People Officer, effective immediately.

January 5, 2022
·
3 min read
Pharm Country

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins

Oramed Pharmaceuticals Inc. announced the European Patent Office has granted the Company a patent titled “Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same.”

January 5, 2022
·
4 min read
Biotech Bay

Invitae to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Invitae Corporation will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 , at 9:45 a.m. Eastern Time .

January 5, 2022
·
1 min read
BioCapital

KeifeRx to Participate in H.C. Wainwright BioConnect 2022 Conference and BIO Partnering at JPM

KeifeRx, LLC, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative diseases, announced that the Company is participating in the H.C. Wainwright BioConnect 2022 Conference and BIO Partnering at JPM.

January 5, 2022
·
2 min read
Deals

Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine Through Its Pipeline of RNA Editing Programs

Financing led by Eventide Asset Management with participation from a strong syndicate of new and existing investors.

January 5, 2022
·
3 min read
Genetown

Korro Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

Korro Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference.

January 5, 2022
·
1 min read
Business

Nationally Recognized Ophthalmologist Dr. Elizabeth Yeu Joins Avellino’s Board of Directors

Avellino Lab USA, Inc. announced the appointment of Dr. Elizabeth Yeu to the company’s Board of Directors.

January 5, 2022
·
4 min read
Pharm Country

Gennao Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

Gennao Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference.

January 5, 2022
·
1 min read